Skeletal muscle loss: cachexia, sarcopenia, and inactivity

被引:488
作者
Evans, William J. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA
关键词
BODY-COMPOSITION; BED-REST; ENERGY-EXPENDITURE; PROTEIN-SYNTHESIS; CANCER CACHEXIA; HEART-FAILURE; WEIGHT-LOSS; MASS; STRENGTH; WOMEN;
D O I
10.3945/ajcn.2010.28608A
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Loss of skeletal muscle mass occurs during aging (sarcopenia), disease (cachexia), or inactivity (atrophy). This article contrasts and compares the metabolic causes of loss of muscle resulting from these conditions. An understanding of the underlying causes of muscle loss is critical for the development of strategies and therapies to preserve muscle mass and function. Loss of skeletal muscle protein results from an imbalance between the rate of muscle protein synthesis and degradation. Cachexia, sarcopenia, and atrophy due to inactivity are characterized by a loss of muscle mass. Each of these conditions results in a metabolic adaptation of increased protein degradation (cachexia), decreased rate of muscle protein synthesis (inactivity), or an alteration in both (sarcopenia). The clinical consequences of bedrest may mimic those of cachexia, including rapid loss of muscle, insulin resistance, and weakness. Prophylaxis against bedrest-induced atrophy includes nutrition support with an emphasis on high-quality protein. Nutritional supplementation alone may not prevent muscle loss secondary to cachexia, but, in combination with the use of an anabolic agent, it may slow or prevent muscle loss. Am J Clin Nutr 2010;91(suppl):1123S-7S.
引用
收藏
页码:1123S / 1127S
页数:5
相关论文
共 54 条
[1]   Cancer cachexia is regulated by selective targeting of skeletal muscle gene products [J].
Acharyya, S ;
Ladner, KJ ;
Nelsen, LL ;
Damrauer, J ;
Reiser, PJ ;
Swoap, S ;
Guttridge, DC .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) :370-378
[2]   NF-κB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight [J].
Agustí, A ;
Morlá, M ;
Sauleda, J ;
Saus, C ;
Busquets, X .
THORAX, 2004, 59 (06) :483-487
[3]  
Anker SD, 1998, EUR HEART J, V19, P191
[4]   Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study [J].
Anker, SD ;
Negassa, A ;
Coats, AJS ;
Afzal, R ;
Poole-Wilson, PA ;
Cohn, JN ;
Yusuf, S .
LANCET, 2003, 361 (9363) :1077-1083
[5]  
[Anonymous], NATL HLTH STAT REPOR
[6]   Epidemiology of sarcopenia among the elderly in New Mexico [J].
Baumgartner, RN ;
Koehler, KM ;
Gallagher, D ;
Romero, L ;
Heymsfield, SB ;
Ross, RR ;
Garry, PJ ;
Lindeman, RD .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (08) :755-763
[7]   Sarcopenia, obesity, and inflammation - results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study [J].
Cesari, M ;
Kritchevsky, SB ;
Baumgartner, RN ;
Atkinson, HH ;
Penninx, BWHJ ;
Lenchik, L ;
Palla, SL ;
Ambrosius, WT ;
Tracy, RP ;
Pahor, M .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2005, 82 (02) :428-434
[8]  
Cesari M, 2004, J GERONTOL A-BIOL, V59, P242
[9]   Endocrinological disturbances in chronic obstructive pulmonary disease [J].
Creutzberg, EC ;
Casaburi, R .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 :76S-80S
[10]   The influence of prolonged muscular rest on metabolism. [J].
Cuthbertson, DP .
BIOCHEMICAL JOURNAL, 1929, 23 (06) :1328-1345